The Pharmaceutical Services Directory is a global directory of thousands of pharmaceutical suppliers connecting them within their marketplace. It brings together both buyers and sellers of products and services providing a secure digital platform for identification and verification processes, in a highly regulated industry and marketplace.
Access to the platform is subscription based. There is lots of opportunity to have direct links and connect and collaborate with a wide range of companies. The directory has a targeted and registered pharma global audience giving you the opportunity to receive valuble leads for your business.
Also available through our platform is SURIMS' Supplier Management Software. This is SaaS software which enables and supports the successful identification, qualification, auditing and collaboration with preferred pharma vendors and technical partners, found either through the directory or independently.
This Directory is a unique universe of pharmaceutical and medical device companies for both buyers and sellers. We bring together quality companies in the following disciplines:
16-Nov-20
Minaris Expands Manufacturing Capacity for Cell and Gene Therapies in Germany and Japan
Minaris Regenerative Medicine
16-Nov-20
Lilly receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19
Eli Lilly
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
16-Nov-20
Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m
Vibalogics GmbH
